Our finding of an under-activation status of CP-CML CD34+ cells signaling is coherent with a low rate of cycling cells and with a reported resistance to cytotoxic cell cycle-related agents. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.